Please login to the form below
Crescendo Biologics appoints CFO
Theodora Harold joins the drug discovery firm
Cambridge, UK-based Crescendo Biologics has appointed Theodora Harold as its new chief financial officer.
Harold brings 20 years of pharmaceutical and corporate finance industry experience to the role, with particular expertise in growing and early stage biotech companies.
She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics.
Dr Peter Pack, chief executive officer of Crescendo Biologics, said: “Theo's appointment as Crescendo's new chief financial officer places us in an excellent position to drive ahead with our ambitious plans to create a high value pipeline of differentiated Humabody therapeutics for treating cancer indications with substantial unmet need.
“The experience that she brings to Crescendo strengthens the existing management team and is crucial in allowing us to continue building both strategic and financial value in the company.”
Subscribe to our email news alerts
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
- Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults
- New report reveals antibiotic underdosing could be leading cause of AMR in UK
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
No results were found
PMHub
Wallace Health
Wallace Health is a healthcare and medical content agency with a successful track record of delivering web content, content marketing...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
